bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S4 from NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome
Authors: Griffiths Elizabeth A. , Srivastava Pragya , Matsuzaki Junko , Brumberger Zachary , Wang Eunice S. , Kocent Justin , Miller Austin , Roloff Gregory W. , Wong Hong Yuen , Paluch Benjamin E. , Lutgen-Dunckley Linda G. , Martens Brandon L. , Odunsi Kunle , Karpf Adam R. , Hourigan Christopher S. , Nemeth Michael J.
Published: April 2023

Supplemental Figure 4. Identification of conventional DC subsets in MDS patients.
Table S3 from Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma
Authors: Sternberg Cora N. , Donskov Frede , Haas Naomi B. , Doehn Christian , Russo Paul , Elmeliegy Mohamed , Baneyx Guillaume , Banerjee Hiya , Aimone Paola , Motzer Robert J.
Published: April 2023

Baseline patient characteristics and variables used in population PK analysis
Figure S3 from NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome
Authors: Griffiths Elizabeth A. , Srivastava Pragya , Matsuzaki Junko , Brumberger Zachary , Wang Eunice S. , Kocent Justin , Miller Austin , Roloff Gregory W. , Wong Hong Yuen , Paluch Benjamin E. , Lutgen-Dunckley Linda G. , Martens Brandon L. , Odunsi Kunle , Karpf Adam R. , Hourigan Christopher S. , Nemeth Michael J.
Published: April 2023

Supplemental Figure 3. Effect of combination of NY-ESO-1 vaccine and decitabine treatment on the frequencies of regulatory T-lymphocytes (TRegs).
Table S2 from Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma
Authors: Sternberg Cora N. , Donskov Frede , Haas Naomi B. , Doehn Christian , Russo Paul , Elmeliegy Mohamed , Baneyx Guillaume , Banerjee Hiya , Aimone Paola , Motzer Robert J.
Published: April 2023

Quartiles for pazopanib steady-state early and late Ctrough
Table S1 from Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma
Authors: Sternberg Cora N. , Donskov Frede , Haas Naomi B. , Doehn Christian , Russo Paul , Elmeliegy Mohamed , Baneyx Guillaume , Banerjee Hiya , Aimone Paola , Motzer Robert J.
Published: April 2023

Clinical studies of pazopanib contributing to the historical dataset for population PK analyses
Figure S2 from Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma
Authors: Sternberg Cora N. , Donskov Frede , Haas Naomi B. , Doehn Christian , Russo Paul , Elmeliegy Mohamed , Baneyx Guillaume , Banerjee Hiya , Aimone Paola , Motzer Robert J.
Published: April 2023

Mean (95% CI) of simulated pazopanib steady state exposure metrics on day 28 by dose in historical (black) and PROTECT (red) populations under fasted state
Requirement of IRAK1/4 for AI growth of PDAC cells from Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma
Authors: Zhang Daoxiang , Li Lin , Jiang Hongmei , Knolhoff Brett L. , Lockhart Albert C. , Wang-Gillam Andrea , DeNardo David G. , Ruzinova Marianna B. , Lim Kian-Huat
Published: April 2023

Supplementary Figure 2. Requirement of IRAK1/4 for AI growth of PDAC cells.
Supplementary Dataset from MITF-High and MITF-Low Cells and a Novel Subpopulation Expressing Genes of Both Cell States Contribute to Intra- and Intertumoral Heterogeneity of Primary Melanoma
Authors: Ennen Marie , Keime Céline , Gambi Giovanni , Kieny Alice , Coassolo Sebastien , Thibault-Carpentier Christelle , Margerin-Schaller Fanny , Davidson Guillaume , Vagne Constance , Lipsker Dan , Davidson Irwin
Published: April 2023

List of genes and primers used
Table S1 from Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells
Authors: Niu Xiaojia , Zhao Jianyun , Ma Jun , Xie Chengzhi , Edwards Holly , Wang Guan , Caldwell J. Timothy , Xiang Shengyan , Zhang Xiaohong , Chu Roland , Wang Zhihong J. , Lin Hai , Taub Jeffrey W. , Ge Yubin
Published: April 2023

Table S1
Supplemental Figures from Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells
Authors: Niu Xiaojia , Zhao Jianyun , Ma Jun , Xie Chengzhi , Edwards Holly , Wang Guan , Caldwell J. Timothy , Xiang Shengyan , Zhang Xiaohong , Chu Roland , Wang Zhihong J. , Lin Hai , Taub Jeffrey W. , Ge Yubin
Published: April 2023

Supplemental Figures
Supplementary Tables from ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors
Authors: Guerrero-Zotano Angel L. , Stricker Thomas P. , Formisano Luigi , Hutchinson Katherine E. , Stover Daniel G. , Lee Kyung-Min , Schwarz Luis J. , Giltnane Jennifer M. , Estrada Monica V. , Jansen Valerie M. , Servetto Alberto , Gavilá Joaquín , Perez-Fidalgo J. Alejandro , Lluch Ana , Llombart-Cussac Antonio , Bayar Mohamed Amine , Michiels Stefan , André Fabrice , Arnedos Mónica , Guillem Vicente , Ruiz-Simon Amparo , Arteaga Carlos L.
Published: April 2023

Supplemental Table S1: The Preoperative Endocrine Prognostic Index (PEPI score) Supplemental Table S2:* Baseline Ki67: 7 patients had missing values Supplemental Table S3a: Driver Mutations Supplemental Table S3b: Driver Copy Number Alterations Supplemental Table S3c: Mutations clinically actionable. Drug prescription Supplemental Table S4: Actionable CNAs. Drug prescription Supplemental Table S5: Overlap between genes upregulated in resistant tumors and transcription factor targets genes Suplemental Table S6: Change from baseline to surgery in gene expressions of the 47 most upregulated genes in the tumors resistant to prolonged neoadjuvant letrozole from 60 HR-positive/HER2-negative breast cancers in POP trial. A decreased gene expression translates into a geometric mean change < 1 . An increased or stable gene expression translates into a geometric mean change {greater than or equal to} 1. Supplemental Table S7: Mutations detected in this study(post-filtering) Supplemental Table S8: Gene expression values (FPKM)
Figure S1 from ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors
Authors: Guerrero-Zotano Angel L. , Stricker Thomas P. , Formisano Luigi , Hutchinson Katherine E. , Stover Daniel G. , Lee Kyung-Min , Schwarz Luis J. , Giltnane Jennifer M. , Estrada Monica V. , Jansen Valerie M. , Servetto Alberto , Gavilá Joaquín , Perez-Fidalgo J. Alejandro , Lluch Ana , Llombart-Cussac Antonio , Bayar Mohamed Amine , Michiels Stefan , André Fabrice , Arnedos Mónica , Guillem Vicente , Ruiz-Simon Amparo , Arteaga Carlos L.
Published: April 2023

CONSORT diagram
Supplementary File 2 from Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer
Authors: West Diana C. , Kocherginsky Masha , Tonsing-Carter Eva Y. , Dolcen D. Nesli , Hosfield David J. , Lastra Ricardo R. , Sinnwell Jason P. , Thompson Kevin J. , Bowie Kathleen R. , Harkless Ryan V. , Skor Maxwell N. , Pierce Charles F. , Styke Sarah C. , Kim Caroline R. , de Wet Larischa , Greene Geoffrey L. , Boughey Judy C. , Goetz Matthew P. , Kalari Krishna R. , Wang Liewei , Fleming Gini F. , Györffy Balázs , Conzen Suzanne D.
Published: April 2023

Details about the n=232 putative direct GR targets and Dex GR peaks that are loss, gained, or conserved upon addition of GR antagonists.
Supplementary File 1 from Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer
Authors: West Diana C. , Kocherginsky Masha , Tonsing-Carter Eva Y. , Dolcen D. Nesli , Hosfield David J. , Lastra Ricardo R. , Sinnwell Jason P. , Thompson Kevin J. , Bowie Kathleen R. , Harkless Ryan V. , Skor Maxwell N. , Pierce Charles F. , Styke Sarah C. , Kim Caroline R. , de Wet Larischa , Greene Geoffrey L. , Boughey Judy C. , Goetz Matthew P. , Kalari Krishna R. , Wang Liewei , Fleming Gini F. , Györffy Balázs , Conzen Suzanne D.
Published: April 2023

Patient and tumor prognostic values of study cohorts and a flow chart of the study design.
Supplementary Table S1-S5 from Neddylation Blockade Diminishes Hepatic Metastasis by Dampening Cancer Stem-Like Cells and Angiogenesis in Uveal Melanoma
Authors: Jin Yanli , Zhang Ping , Wang Yun , Jin Bei , Zhou Jingfeng , Zhang Jing , Pan Jingxuan
Published: April 2023

Table S1 shows genetic status of the known altered genes in UM cell lines; Table S2 shows detailed information for 45 patients with UM; Table S3 shows the association between NAE1 expression and clinicopathologic features in UM patients; Table S4 shows limiting dilution analysis in NOD-SCID mice; Table S5 shows primers for qRT-PCR analysis.
Supplementary Figures from Neddylation Blockade Diminishes Hepatic Metastasis by Dampening Cancer Stem-Like Cells and Angiogenesis in Uveal Melanoma
Authors: Jin Yanli , Zhang Ping , Wang Yun , Jin Bei , Zhou Jingfeng , Zhang Jing , Pan Jingxuan
Published: April 2023

Figure S1-The specificity of NAE1 antibody for immunohistochemical analysis was verified; Figure S2-MLN4924 induces apoptosis in human UM cells; Figure S3-MLN4924 is synergistic with vinblastine to induce apoptosis in UM cells; Figure S4-MLN4924 induces DNA damage response and G2/M-phase arrest in UM cells; Figure S5-Inhibiting checkpoint of DNA damage potentiates the cytotoxicity of MLN4924; Figure S6-MLN4924 suppresses ALDH+ cells in UM cells; Figure S7-Slug is required for maintenance of CSCs properties in UM cells; Figure S8-MLN4924 inhibits migration and invasion of human UM cells; Figure S9-MLN4924 inhibits hepatic metastasis of UM cells by attenuating VEGF-C secretion.
Supplementary Table 5-6 from Long Noncoding RNA NEAT1, Regulated by the EGFR Pathway, Contributes to Glioblastoma Progression Through the WNT/β-Catenin Pathway by Scaffolding EZH2
Authors: Chen Qun , Cai Jinquan , Wang Qixue , Wang Yunfei , Liu Mingyang , Yang Jingxuan , Zhou Junhu , Kang Chunsheng , Li Min , Jiang Chuanlu
Published: April 2023

Supplementary Table 5: RNA seq data Supplementary Table 6: Clinical data
Figure S1-8 from Long Noncoding RNA NEAT1, Regulated by the EGFR Pathway, Contributes to Glioblastoma Progression Through the WNT/β-Catenin Pathway by Scaffolding EZH2
Authors: Chen Qun , Cai Jinquan , Wang Qixue , Wang Yunfei , Liu Mingyang , Yang Jingxuan , Zhou Junhu , Kang Chunsheng , Li Min , Jiang Chuanlu
Published: April 2023

Supplementary Figure 1. NEAT1 is a potential EGFR-driven lncRNA, as demonstrated through bioinformatics analysis, and the status of EGFR (or EGFRvIII), p53, PDGFR in patient-derived cells are validated by Western blot. Supplementary Figure 2. NEAT1 is an abundant nuclear lncRNA that could be knocked down through the dual CRISPR/Cas9 system in glioblastoma cells. Supplementary Figure 3. Knockdown of NEAT1 inhibits proliferation, invasion and clone formation and induces cell apoptosis in glioblastoma cells. Supplementary Figure 4. Knockdown of NEAT1 promotes WNT/β-Catenin negative feedback factor expression in N5 and N9 cells. Supplementary Figure 5. Knockdown of NEAT1 level inhibits β-Catenin in N5 and N9 cells. Supplementary Figure 6. The correlation analysis among DNA methylation, DNA copy number and NEAT1 expression profiles in TCGA GBM database. Supplementary Figure 7. NEAT1 is an evolutionarily conserved lncRNA and may bind to EZH2. Supplementary Figure 8. NEAT1 does not bind with DNMT1; the expression of NEAT1_1, NEAT1_2 and MALAT1 are detected when glioblastoma cells were treated with HOTAIR associated virus, and the H3K27Me3 level in different NEAT1 treatment groups is detected.
Supplemental Methods from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
Authors: Horn Leora , Infante Jeffrey R. , Reckamp Karen L. , Blumenschein George R. , Leal Ticiana A. , Waqar Saiama N. , Gitlitz Barbara J. , Sanborn Rachel E. , Whisenant Jennifer G. , Du Liping , Neal Joel W. , Gockerman Jon P. , Dukart Gary , Harrow Kimberly , Liang Chris , Gibbons James J. , Holzhausen Allison , Lovly Christine M. , Wakelee Heather A.
Published: April 2023

Supplemental Methods
Supplemental Figure 2 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
Authors: Horn Leora , Infante Jeffrey R. , Reckamp Karen L. , Blumenschein George R. , Leal Ticiana A. , Waqar Saiama N. , Gitlitz Barbara J. , Sanborn Rachel E. , Whisenant Jennifer G. , Du Liping , Neal Joel W. , Gockerman Jon P. , Dukart Gary , Harrow Kimberly , Liang Chris , Gibbons James J. , Holzhausen Allison , Lovly Christine M. , Wakelee Heather A.
Published: April 2023

Supplemental Figure 2. Arithmetic mean concentration-time curves for fasted patients receiving 225 mg of ensartinib on Days 1 and 22 of Cycle 1.
Supplemental materials and methods from Hyperpolarized [1-13C]-Pyruvate Magnetic Resonance Spectroscopic Imaging of Prostate Cancer In Vivo Predicts Efficacy of Targeting the Warburg Effect
Authors: Scroggins Bradley T. , Matsuo Masayuki , White Ayla O. , Saito Keita , Munasinghe Jeeva P. , Sourbier Carole , Yamamoto Kazutoshi , Diaz Vivian , Takakusagi Yoichi , Ichikawa Kazuhiro , Mitchell James B. , Krishna Murali C. , Citrin Deborah E.
Published: April 2023

Supplemental materials and methods
Supplemental Figures from Hyperpolarized [1-13C]-Pyruvate Magnetic Resonance Spectroscopic Imaging of Prostate Cancer In Vivo Predicts Efficacy of Targeting the Warburg Effect
Authors: Scroggins Bradley T. , Matsuo Masayuki , White Ayla O. , Saito Keita , Munasinghe Jeeva P. , Sourbier Carole , Yamamoto Kazutoshi , Diaz Vivian , Takakusagi Yoichi , Ichikawa Kazuhiro , Mitchell James B. , Krishna Murali C. , Citrin Deborah E.
Published: April 2023

Supplemental Figures
Figure S2 from Merkel Cell Carcinoma Patients Presenting Without a Primary Lesion Have Elevated Markers of Immunity, Higher Tumor Mutation Burden, and Improved Survival
Authors: Vandeven Natalie , Lewis Christopher W. , Makarov Vladimir , Riaz Nadeem , Paulson Kelly G. , Hippe Daniel , Bestick Amy , Doumani Ryan , Marx Tessa , Takagishi Seesha , Chan Timothy A. , Choi Jaehyuk , Nghiem Paul
Published: April 2023

Supplemental Figure 2. MCC-UP status predicts better survival among non-immunosuppressed patients with either stage IIIB or IV disease. Panel A depicts MCC-specific survival B illustrates overall survival and C indicated recurrence-free survival for 92 patients with stage IIIB MCC by unknown primary status. Panel D describes MCC-specific survival for 19 patients with stage IV MCC. MCC-specific survival analyses was completed using a competing-risks regression model with the competing risk being defined as death by all causes except MCC. Overall and recurrence-free survival was performed using the Cox-proportional hazards model.
Supplementary Figure 1 from Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure
Authors: Schneider Bryan P. , Shen Fei , Gardner Laura , Radovich Milan , Li Lang , Miller Kathy D. , Jiang Guanglong , Lai Dongbing , O'Neill Anne , Sparano Joseph A. , Davidson Nancy E. , Cameron David , Gradus-Pizlo Irmina , Mastouri Ronald A. , Suter Thomas M. , Foroud Tatiana , Sledge George W.
Published: April 2023

Genome wide genotyping of E5103 samples. Quality controls for GWAS.
Supplemental table 1 from Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure
Authors: Schneider Bryan P. , Shen Fei , Gardner Laura , Radovich Milan , Li Lang , Miller Kathy D. , Jiang Guanglong , Lai Dongbing , O'Neill Anne , Sparano Joseph A. , Davidson Nancy E. , Cameron David , Gradus-Pizlo Irmina , Mastouri Ronald A. , Suter Thomas M. , Foroud Tatiana , Sledge George W.
Published: April 2023

Top SNPs associated with anthracycline induced CHF
Supplementary Tables from Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer
Authors: Gupta Santosh , Li Jing , Kemeny Gabor , Bitting Rhonda L. , Beaver Joshua , Somarelli Jason A. , Ware Kathryn E. , Gregory Simon , Armstrong Andrew J.
Published: April 2023

Table S1: Clinical characteristics of the men with mCRPC who contributed CTC data for this analysis; Table S2: Ingenuity network and pathway analysis (IPA) in AR-amplified samples. Table represents canonical pathways enriched in at least 50% of cases of AR -amplified CTCs samples; Table S3: Ingenuity network and pathway analysis in AR copy neutral patients. Table represents enriched canonical pathways in AR copy neutral CTCs samples.
Supplementary Figure 5 from Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting
Authors: Slaney Clare Y. , von Scheidt Bianca , Davenport Alexander J. , Beavis Paul A. , Westwood Jennifer A. , Mardiana Sherly , Tscharke David C. , Ellis Sarah , Prince H. Miles , Trapani Joseph A. , Johnstone Ricky W. , Smyth Mark J. , Teng Michele W. , Ali Aesha , Yu Zhiya , Rosenberg Steven A. , Restifo Nicholas P. , Neeson Paul , Darcy Phillip K. , Kershaw Michael H.
Published: April 2023

CARaMEL T cells persist in long term surviving mice.
Figure S2 from Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study
Authors: Moeung Sotheara , Chevreau Christine , Broutin Sophie , Guitton Jérôme , Lelièvre Bénédicte , Ciccolini Joseph , Massart Christophe , Fléchon Aude , Delva Rémy , Gravis Gwenaëlle , Lotz Jean-Pierre , Bay Jacques-Olivier , Gross-Goupil Marine , Paci Angelo , Marsili Sabrina , Malard Laurence , Chatelut Etienne , Thomas Fabienne
Published: April 2023

Weighted residuals (WRES) and individual weighted residuals (IWRES) versus population predicted concentrations (PRED) plots obtained from NONMEM analysis on C1D1 data of the 89 patients of the PK study.
Supplemental Table 1 from Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma
Authors: Yang Qingshan , Chen Lisa S. , Ha Min Jin , Do Kim-Anh , Neelapu Sattva S. , Gandhi Varsha
Published: April 2023

Supplemental Table 1. MCL cell line information.
Supplementary Data from BMP4 Induces M2 Macrophage Polarization and Favors Tumor Progression in Bladder Cancer
Authors: Martínez Víctor G. , Rubio Carolina , Martínez-Fernández Mónica , Segovia Cristina , López-Calderón Fernando , Garín Marina I. , Teijeira Alicia , Munera-Maravilla Ester , Varas Alberto , Sacedón Rosa , Guerrero Félix , Villacampa Felipe , de la Rosa Federico , Castellano Daniel , López-Collazo Eduardo , Paramio Jesús M. , Vicente Ángeles , Dueñas Marta
Published: April 2023

Supplementary Table 1. Bladder Cancer cell lines. Supplementary Table 2. Primers and TaqMan probes used for qPCR. Supplementary Figure 1.Characterization of monocyte/macrophage polarization. Supplementary Figure 2. Resistance of BCCs to monocyte-induced apoptosis Supplementary Figure 3. Macrophage marker evaluation toward tumorigenesis and recurrence Supplementary Figure 4. Analyses of different factors that may influence time to recurrence Supplementary Figure 5.CD 163 expression in Tissue microarrays. Representative positive (A) and negative (B) tumors are shown. Supplementary Figure 6.BMP4 expression on NMIBC and MIBC
Supplementary Data File 2 from Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker
Authors: Pietrasz Daniel , Pécuchet Nicolas , Garlan Fanny , Didelot Audrey , Dubreuil Olivier , Doat Solène , Imbert-Bismut Francoise , Karoui Mehdi , Vaillant Jean-Christophe , Taly Valérie , Laurent-Puig Pierre , Bachet Jean-Baptiste
Published: April 2023

Correlation between Mutation Allelic Frequency (MAF) according to Next Generation Sequencing and picoliter droplet based digital PCR.
Figure S6 from Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
Authors: Xu Chunxiao , Zhang Yanping , Rolfe P. Alexander , Hernández Vivian M. , Guzman Wilson , Kradjian Giorgio , Marelli Bo , Qin Guozhong , Qi Jin , Wang Hong , Yu Huakui , Tighe Robert , Lo Kin-Ming , English Jessie M. , Radvanyi Laszlo , Lan Yan
Published: April 2023

Heatmap of selected genes from a Nanostring gene expression panel.
Figure S4 from Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
Authors: Xu Chunxiao , Zhang Yanping , Rolfe P. Alexander , Hernández Vivian M. , Guzman Wilson , Kradjian Giorgio , Marelli Bo , Qin Guozhong , Qi Jin , Wang Hong , Yu Huakui , Tighe Robert , Lo Kin-Ming , English Jessie M. , Radvanyi Laszlo , Lan Yan
Published: April 2023

PD-L1 is expressed on TILs, but not tumor cells, in EMT-6 tumors.
Supplementary table S6 from A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases
Authors: Montfort Anne , Pearce Oliver , Maniati Eleni , Vincent Benjamin G. , Bixby Lisa , Böhm Steffen , Dowe Thomas , Wilkes Edmund H. , Chakravarty Probir , Thompson Richard , Topping Joanne , Cutillas Pedro R. , Lockley Michelle , Serody Jonathan S. , Capasso Melania , Balkwill Frances R.
Published: April 2023

Sequences of primers used to perform the BCR sequencing analyses
Supplementary Table 1. Associations between clinical and histopathologic parameters are metastasis (Fisher's exact tests). from Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases
Authors: Nagarajan Priyadharsini , Curry Jonathan L. , Ning Jing , Piao Jin , Torres-Cabala Carlos A. , Aung Phyu P. , Ivan Doina , Ross Merrick I. , Levenback Charles F. , Frumovitz Michael , Gershenwald Jeffrey E. , Davies Michael A. , Malpica Anais , Prieto Victor G. , Tetzlaff Michael T.
Published: April 2023

M1a, Metastasis in skin, subcutaneous tissues, or distant lymph nodes; M1b, Metastasis to lung; M1c, Metastasis to all other visceral sites.
Supplemental Table 2. Distribution of primary vulvar melanomas with tumor thickness > 4.00 mm reported in literature. from Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases
Authors: Nagarajan Priyadharsini , Curry Jonathan L. , Ning Jing , Piao Jin , Torres-Cabala Carlos A. , Aung Phyu P. , Ivan Doina , Ross Merrick I. , Levenback Charles F. , Frumovitz Michael , Gershenwald Jeffrey E. , Davies Michael A. , Malpica Anais , Prieto Victor G. , Tetzlaff Michael T.
Published: April 2023

TT, tumor thickness; NR, not reported * Includes vulvar (n=14) and vaginal (n=7) melanomas Â£ Includes vulvar (n=16), vaginal (n=1) and cervical (n=1) melanomas Â¥ Includes vulvar (n=61), vaginal (n=15), urethral (n=5) and cervical (n=4) melanomas Â,¬ Includes vulvar (n=33) and vaginal (n=11) melanomas Î' Includes vulvar (n=58), vaginal (n=11), cervical (n=7) and other (n=9) melanomas
Supplementary Figure and Methods from A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases
Authors: Montfort Anne , Pearce Oliver , Maniati Eleni , Vincent Benjamin G. , Bixby Lisa , Böhm Steffen , Dowe Thomas , Wilkes Edmund H. , Chakravarty Probir , Thompson Richard , Topping Joanne , Cutillas Pedro R. , Lockley Michelle , Serody Jonathan S. , Capasso Melania , Balkwill Frances R.
Published: April 2023

Supplementary Material and Methods describing in vivo, mass spectrometry and immunocytofluorescence experiments; Supplementary Figures 1,2 and 3 and Supplementary figures and tables legends.
Supplemental Figure 1. Correlation between dermal mitotic rate and patient survival. from Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases
Authors: Nagarajan Priyadharsini , Curry Jonathan L. , Ning Jing , Piao Jin , Torres-Cabala Carlos A. , Aung Phyu P. , Ivan Doina , Ross Merrick I. , Levenback Charles F. , Frumovitz Michael , Gershenwald Jeffrey E. , Davies Michael A. , Malpica Anais , Prieto Victor G. , Tetzlaff Michael T.
Published: April 2023

Kaplan-Meier estimate of (A) overall survival and (B) disease-specific survival based on dermal mitotic rate (mitotic figures/mm2).
SUPPLEMENTARY DATA from Body Composition as a Predictor of Toxicity in Patients Receiving Anthracycline and Taxane–Based Chemotherapy for Early-Stage Breast Cancer
Authors: Shachar Shlomit Strulov , Deal Allison M. , Weinberg Marc , Williams Grant R. , Nyrop Kirsten A. , Popuri Karteek , Choi Seul Ki , Muss Hyman B.
Published: April 2023

SUPPLEMENTARY DATA
Supplementary Revised Figure S1 from MUC16 Regulates TSPYL5 for Lung Cancer Cell Growth and Chemoresistance by Suppressing p53
Authors: Lakshmanan Imayavaramban , Salfity Shereen , Seshacharyulu Parthasarathy , Rachagani Satyanarayana , Thomas Abigail , Das Srustidhar , Majhi Prabin D. , Nimmakayala Rama Krishna , Vengoji Raghupathy , Lele Subodh M. , Ponnusamy Moorthy P. , Batra Surinder K. , Ganti Apar Kishor
Published: April 2023

MUC16 incidence in lung cancer. A, MUC16 is overexpressed in a greater proportion of lung adenocarcinoma compared to other histological subtypes. B, Data from TCGA also shows that MUC16 is highly expressed in adenocarcinoma tissues than squamous carcinoma tissues. C, TSPYL5 transcript was significantly decreased in MUC16 knockdown (H292-shMUC16 seq1 and shMUC16 seq2) as validated by quantitative real-time PCR analysis. D, Immunoprecipitation assay demonstrated that STAT3 interacts with GR in lung cancer cells. **P<0.01.
Supplementary figure 1. from A Positive Feedback Loop of lncRNA-PVT1 and FOXM1 Facilitates Gastric Cancer Growth and Invasion
Authors: Xu Mi-die , Wang Yiqin , Weng Weiwei , Wei Ping , Qi Peng , Zhang Qiongyan , Tan Cong , Ni Shu-juan , Dong Lei , Yang Yusi , Lin Wanrun , Xu Qinghua , Huang Dan , Huang Zhaohui , Ma Yuqing , Zhang Wei , Sheng Weiqi , Du Xiang
Published: April 2023

(A) Analysis of PVT1 alteration frequency in GC tissues from TCGA data. (B) Kaplan-Meier survival curves in an independent GC subgroup showed that the DFS (n=359) and DSS (n=593) rates of the high PVT1 expression group were significantly higher than that of the low expression group. The hazard ratios (HRs) and P values were calculated with a log-rank test. (C) Kaplan-Meier survival curves of patients with varying PVT1 expression, which were stratified by lymphatic and distant metastasis status. (Upper) DFS of patients with (N1, n=164) or without (N0, n=26) lymphatic metastasis and DSS of patients with (N1, n=164) or without (N0, n=26) lymphatic metastasis; (Below) DFS of patients with (M1, n=24) or without (M0, n=166) distant metastasis and DSS of patients with (M1, n=24) or without (M0, n=166) distant metastasis. The HRs and P values were calculated with log-rank tests. (D) Kaplan-Meier survival curves for patients with PVT1 expression in the independent cohort, stratified by lymphatic and distant metastasis status. The HRs and P values were calculated with log-rank tests.
Figure S3 from Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus
Authors: Eriksson Emma , Milenova Ioanna , Wenthe Jessica , Ståhle Magnus , Leja-Jarblad Justyna , Ullenhag Gustav , Dimberg Anna , Moreno Raphael , Alemany Ramon , Loskog Angelica
Published: April 2023

Supplementary Figure S3. Gemcitabine titration Human pancreatic cancer cell lines were cultured in increasing concentrations of gemcitabine and subjected to MTS viability assay at 72 hours post culture initiation.
Figure S2 from Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus
Authors: Eriksson Emma , Milenova Ioanna , Wenthe Jessica , Ståhle Magnus , Leja-Jarblad Justyna , Ullenhag Gustav , Dimberg Anna , Moreno Raphael , Alemany Ramon , Loskog Angelica
Published: April 2023

Supplementary Figure S2. Oncolysis over time The human PaCa3 cell line was infected with 100MOI LOAd(-), LOAd700 or LOAd703 virus, or left uninfected. The cells were plated in a 96-well plate in quadruplicates and analyzed by MTS assay at three time points. The plates were analyzed by spectrophotometry at 490nm as per manufacturer instructions. Uninfected cells remained viable while infected cells were killed over time independently of type of LOAd virus demonstrating that the viruses have oncolytic capacity and that the transgene cassette does not interfere with oncolysis.
Supplemental Figures 9 from Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma
Authors: Kalbasi Anusha , Komar Chad , Tooker Graham M. , Liu Mingen , Lee Jae W. , Gladney Whitney L. , Ben-Josef Edgar , Beatty Gregory L.
Published: April 2023

Supplemental Figure 9: CCL2 neutralization, with or without ablative RT, does not induce T cell infiltration into PDAC tumors
Supplemental Figures 5-6 from Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma
Authors: Kalbasi Anusha , Komar Chad , Tooker Graham M. , Liu Mingen , Lee Jae W. , Gladney Whitney L. , Ben-Josef Edgar , Beatty Gregory L.
Published: April 2023

Supplemental Figure 5: Ablative RT induces recruitment of inflammatory monocytes in an orthotopic model of PDAC; Supplemental Figure 6: Impact of ablative RT on inflammatory monocyte/macrophage gene expression
Supplementary table 4 from Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors
Authors: Jdey Wael , Thierry Sylvain , Russo Christophe , Devun Flavien , Al Abo Muthana , Noguiez-Hellin Patricia , Sun Jian-Sheng , Barillot Emmanuel , Zinovyev Andrei , Kuperstein Inna , Pommier Yves , Dutreix Marie
Published: April 2023

Supplementary Table 4. IC20 and IC50 of different PARP inhibitors in MDAMB231 cell line. IC20 and IC50 were calculated according to the dose-response curves of the different PARP inhibitors using GraphPadPrism software.
Supplementary table 2 from Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors
Authors: Jdey Wael , Thierry Sylvain , Russo Christophe , Devun Flavien , Al Abo Muthana , Noguiez-Hellin Patricia , Sun Jian-Sheng , Barillot Emmanuel , Zinovyev Andrei , Kuperstein Inna , Pommier Yves , Dutreix Marie
Published: April 2023

Supplementary Table 2. ACSN functional modules enrichment by unique genes robustly correlated with survival to AsiDNA in BC cell lines. Red - positive correlation, green - negative correlation. (P value <0.02).
Supplementary figure S4 from Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors
Authors: Jdey Wael , Thierry Sylvain , Russo Christophe , Devun Flavien , Al Abo Muthana , Noguiez-Hellin Patricia , Sun Jian-Sheng , Barillot Emmanuel , Zinovyev Andrei , Kuperstein Inna , Pommier Yves , Dutreix Marie
Published: April 2023

Supplementary figure S4. Molecular portraits of resistance to AsiDNA or olaparib in BC cell lines on Atlas of Cancer Signaling Networks. Molecular portraits generated for two groups of BC cell lines that demonstrate resistance to (A) AsiDNA or (B) Ola using expression, copy number variations and mutation frequency, projected on ACSN global map (Supplementary Figure S3-B). Red and green background colors respectively represent high and low mRNA expression levels across genes of a same pathway; intensity of color shows the level of the change to the mean value of the BC cell lines group. Copy number variations are represented as glyphs where yellow squares indicated copy number gains and blue indicate copy number losses. Mutations are represented using cyan diamonds. The data is displayed at the top level zoom demonstrating a pattern of data distribution across biological processes.
Supplementary figure S1 from Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors
Authors: Jdey Wael , Thierry Sylvain , Russo Christophe , Devun Flavien , Al Abo Muthana , Noguiez-Hellin Patricia , Sun Jian-Sheng , Barillot Emmanuel , Zinovyev Andrei , Kuperstein Inna , Pommier Yves , Dutreix Marie
Published: April 2023

Supplementary figure S1. Synergy between AsiDNA and PARP defect in DT40 cells. (A) Cytotoxicity of AsiDNA toward various isogenic DT40 cell lines. (B) Comparison of cell survival to AsiDNA in DT40 cells wild-type (WT; black) or PARP KO (red) alone (continuous line) or in combination with veliparib 1µM (blue discontinuous line). Survivals were monitored by ATPlite 1-step kit (72 hours after treatment) in various mutant DT40 cells as described in (36). Survival is expressed as % of non-treated cells. Results are represented as mean survival {plus minus} SEM for three independent experiments.
Supplementary Table 1 from Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms
Authors: Lee JongBok , Minden Mark D. , Chen Weihsu C. , Streck Elena , Chen Branson , Kang Hyeonjeong , Arruda Andrea , Ly Dalam , Der Sandy D. , Kang Sohyeong , Achita Paulina , D'Souza Cheryl , Li Yueyang , Childs Richard W. , Dick John E. , Zhang Li
Published: April 2023

Table S1. Clinical information of the 46 AML patients who provided AML cells for in vitro or in vivo assays.
Supplemental figure 4 from Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum
Authors: Hulbert Alicia , Jusue-Torres Ignacio , Stark Alejandro , Chen Chen , Rodgers Kristen , Lee Beverly , Griffin Candace , Yang Andrew , Huang Peng , Wrangle John , Belinsky Steven A. , Wang Tza-Huei , Yang Stephen C. , Baylin Stephen B. , Brock Malcolm V. , Herman James G.
Published: April 2023

Variable importance plot for random forest prediction
Supplementary Table 1 from Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor
Authors: Zook Phillip , Pathak Harsh B. , Belinsky Martin G. , Gersz Lawrence , Devarajan Karthik , Zhou Yan , Godwin Andrew K. , von Mehren Margaret , Rink Lori
Published: April 2023

IC50 and IC80 values calculated from viability data after treatment with single agents or combination (3:1 molar ratio of MK-2206:IM).
Supplemental figure 3 from Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum
Authors: Hulbert Alicia , Jusue-Torres Ignacio , Stark Alejandro , Chen Chen , Rodgers Kristen , Lee Beverly , Griffin Candace , Yang Andrew , Huang Peng , Wrangle John , Belinsky Steven A. , Wang Tza-Huei , Yang Stephen C. , Baylin Stephen B. , Brock Malcolm V. , Herman James G.
Published: April 2023

Receiver operator classification curves for lung cancer detection for the genes obtained from Plasma
Supplemental Figure 1 from Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor
Authors: Zook Phillip , Pathak Harsh B. , Belinsky Martin G. , Gersz Lawrence , Devarajan Karthik , Zhou Yan , Godwin Andrew K. , von Mehren Margaret , Rink Lori
Published: April 2023

Cleaved caspase-3 is enhanced in combination-treated tumors.
Supplementary Tables from miRNA-487a Promotes Proliferation and Metastasis in Hepatocellular Carcinoma
Authors: Chang Rui-Min , Xiao Shuai , Lei Xiong , Yang Hao , Fang Feng , Yang Lian-Yue
Published: April 2023

Supplementary Tables Table S1. Clinicopathologcal Characteristics of The Patients in Training Cohort and in Validation Cohort Table S2. The Association of miR-487a with Clinicopathological Features of HCC in Training Cohort Table S3. The Association of miR-487a with Clinicopathological Features of HCC in Validation Cohort Table S4. Univariate and Multivariate Analysis of Factors Associated with Overall Survival in Training Cohort Table S5. Univariate and Multivariate Analysis of Factors Associated with Disease-Free Survival in Training Cohort Table S6. Univariate and Multivariate Analysis of Factors Associated with Overall Survival in Validation Cohort. Table S7. Univariate and Multivariate Analysis of Factors Associated with Disease-Free Survival in Validation Cohort.
Supplementary Material and Methods from miRNA-487a Promotes Proliferation and Metastasis in Hepatocellular Carcinoma
Authors: Chang Rui-Min , Xiao Shuai , Lei Xiong , Yang Hao , Fang Feng , Yang Lian-Yue
Published: April 2023

Supplementary Material and Methods
Supplementary Figure S1 from Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer
Authors: Mameri Hamza , Bièche Ivan , Meseure Didier , Marangoni Elisabetta , Buhagiar-Labarchède Géraldine , Nicolas André , Vacher Sophie , Onclercq-Delic Rosine , Rajapakse Vinodh , Varma Sudhir , Reinhold William C. , Pommier Yves , Amor-Guéret Mounira
Published: April 2023

CDA expression levels in cancer cell lines and tissues.
Supplementary Figure 5 from An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers
Authors: Dama Elisa , Melocchi Valentina , Dezi Fabio , Pirroni Stefania , Carletti Rose Mary , Brambilla Daniela , Bertalot Giovanni , Casiraghi Monica , Maisonneuve Patrick , Barberis Massimo , Viale Giuseppe , Vecchi Manuela , Spaggiari Lorenzo , Bianchi Fabrizio , Di Fiore Pier Paolo
Published: April 2023

IPA analysis of the NFE2L2 modulator
Supplementary Information from Stabilization of Notch1 by the Hsp90 Chaperone is Crucial for T-Cell Leukemogenesis
Authors: Wang Zhaojing , Hu Yufeng , Xiao Daibiao , Wang Jingchao , Liu Chuntao , Xu Yisheng , Shi Xiaomeng , Jiang Peng , Huang Liang , Li Peng , Liu Hudan , Qing Guoliang
Published: April 2023

Supplementary tables, figures and materials
Supplementary Figure 4 from An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers
Authors: Dama Elisa , Melocchi Valentina , Dezi Fabio , Pirroni Stefania , Carletti Rose Mary , Brambilla Daniela , Bertalot Giovanni , Casiraghi Monica , Maisonneuve Patrick , Barberis Massimo , Viale Giuseppe , Vecchi Manuela , Spaggiari Lorenzo , Bianchi Fabrizio , Di Fiore Pier Paolo
Published: April 2023

Molecular characteristics of different groups of TCGA lung adenocarcinoma patients
Supplemental Tables from An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers
Authors: Dama Elisa , Melocchi Valentina , Dezi Fabio , Pirroni Stefania , Carletti Rose Mary , Brambilla Daniela , Bertalot Giovanni , Casiraghi Monica , Maisonneuve Patrick , Barberis Massimo , Viale Giuseppe , Vecchi Manuela , Spaggiari Lorenzo , Bianchi Fabrizio , Di Fiore Pier Paolo
Published: April 2023

Supplemental Legends Supplemental Table 1.TaqMan Assays Supplemental Table 2. 10-gene model Supplemental Table 3. Cut-offs Supplemental Table 4. Clinical and pathological characteristics of Stage II-III cohort Supplemental Table 7. Causes of death in Training and Validation Sets Supplemental Table 8. Stage I - C1 smoking status Supplemental Table 12A. KEAP1 Mutation in TCGA patients Supplemental Table 12B. KEAP1 copy-number variants in TCGA patients Supplemental Table 12C. KEAP1 promoter methylation in TCGA patients Supplemental Table 13. Mutation, Copy Number Variation and Methylation in C1-patients (TCGA) of KEAP1 and NRF2 genes. Supplemental Table 14. Patient and tumor characteristics of a subgroup of 50 patients from the stage I IEO cohort.
Figure S1-S3 from The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis
Authors: Xu Lei , Mao Xueying , Guo Tianyu , Chan Pui Ying , Shaw Greg , Hines John , Stankiewicz Elzbieta , Wang Yuqin , Oliver R. Tim D. , Ahmad Amar Sabri , Berney Daniel , Shamash Jonathan , Lu Yong-Jie
Published: April 2023

Supplementary Figure 1-3. Fig. S1 Representative five rounds of FISH images in a PC3 cell; Fig. S2 Box plots of CRS and BigNeg cell count; Fig. S3 Kaplan-Meier survival analysis by sub-populations of CTCs.
Table S2 from Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy
Authors: Rogers Laura M. , Mott Sarah L. , Smith Brian J. , Link Brian K. , Sahin Deniz , Weiner George J.
Published: April 2023

GAUSS patient demographics
Suppl. Figs from Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial
Authors: Exley Mark A. , Friedlander Phillip , Alatrakchi Nadia , Vriend Lianne , Yue Simon , Sasada Tetsuro , Zeng Wanyong , Mizukami Yo , Clark Justice , Nemer David , LeClair Kenneth , Canning Christine , Daley Heather , Dranoff Glenn , Giobbie-Hurder Anita , Hodi F. Stephen , Ritz Jerome , Balk Steven P.
Published: April 2023

Suppl. Figs
Suppl. Figs Legends from Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial
Authors: Exley Mark A. , Friedlander Phillip , Alatrakchi Nadia , Vriend Lianne , Yue Simon , Sasada Tetsuro , Zeng Wanyong , Mizukami Yo , Clark Justice , Nemer David , LeClair Kenneth , Canning Christine , Daley Heather , Dranoff Glenn , Giobbie-Hurder Anita , Hodi F. Stephen , Ritz Jerome , Balk Steven P.
Published: April 2023

Suppl. Figs Legends
Biomarker Appendix from BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer
Authors: Benson Al B. , Kiss Igor , Bridgewater John , Eskens Ferry A.L.M. , Sasse Carolyn , Vossen Sandra , Chen Jihong , Van Sant Chip , Ball Howard A. , Keating Anne , Krivoshik Andrew
Published: April 2023

Biomarker Appendix
Supplemental Figure 2 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells
Authors: Ozawa Hiroyuki , Ranaweera Ruchira S. , Izumchenko Evgeny , Makarev Eugene , Zhavoronkov Alex , Fertig Elana J. , Howard Jason D. , Markovic Ana , Bedi Atul , Ravi Rajani , Perez Jimena , Le Quynh-Thu , Kong Christina S. , Jordan Richard C. , Wang Hao , Kang Hyunseok , Quon Harry , Sidransky David , Chung Christine H.
Published: April 2023

Western blot analysis of SCC61L-SC and SMAD4KD cells for phospho-SMAD2 and total SMAD2/3 expression levels. Actin was used as a loading control.
Figure S5 from Downregulation of MicroRNA-644a Promotes Esophageal Squamous Cell Carcinoma Aggressiveness and Stem Cell–like Phenotype via Dysregulation of PITX2
Authors: Zhang Jia-Xing , Chen Zhen-Hua , Xu Yi , Chen Jie-Wei , Weng Hui-Wen , Yun Miao , Zheng Zou-San , Chen Cui , Wu Bing-Li , Li En-Min , Fu Jian-Hua , Ye Sheng , Xie Dan
Published: April 2023

Correlation between the expressions of miR-644a and pluripotency-associated factors in 20 fresh ESCC tissues. A, real-time PCR analysis of the mRNA expression of pluripotency-associated factors, including ABCG2, SOX2, OCT4, NANOG, BMI1, and CD44 in 20 ESCC samples. B, the levels of miR-644a were negatively correlated with the expression levels of pluripotency-associated factors in 20 ESCC tissues. **P<0.01, *P<0.05.
Supplemental Table S1 from High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial
Authors: Nielsen Torsten O. , Jensen Maj-Brit , Burugu Samantha , Gao Dongxia , Jørgensen Charlotte L. Tykjaer , Balslev Eva , Ejlertsen Bent
Published: April 2023

Chemotherapy-related amenorrhea in relation to subtype and disease-free survival
Supplementary methods and figure legends from Circular RNA ciRS-7—A Promising Prognostic Biomarker and a Potential Therapeutic Target in Colorectal Cancer
Authors: Weng Wenhao , Wei Qing , Toden Shusuke , Yoshida Kazuhiro , Nagasaka Takeshi , Fujiwara Toshiyoshi , Cai Sanjun , Qin Huanlong , Ma Yanlei , Goel Ajay
Published: April 2023

Supplementary methods and figure legends
Supplemental data from The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia
Authors: Vercruysse Thomas , De Bie Jolien , Neggers Jasper E. , Jacquemyn Maarten , Vanstreels Els , Schmid-Burgk Jonathan L. , Hornung Veit , Baloglu Erkan , Landesman Yosef , Senapedis William , Shacham Sharon , Dagklis Antonis , Cools Jan , Daelemans Dirk
Published: April 2023

Supplementary Table 1 - EC50 values for KPT-8602 and KPT-330 in different leukemia cells Supplementary Table 2 - EC50 values for KPT-8602 in wild-type versus XPO1C528S mutant cell lines Figure S1 - High content images of HeLa cells stably expressing the NLS-AcGFP-NES reporter treated with different concentrations KPT-330 or KPT-8602 Figure S2 - Effect of KPT-8602 treatment on normal peripheral blood cells of NSG mice
Supplementary Figures 1-2, Supplementary Table 1 from Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug Conjugates
Authors: Hinrichs Mary Jane Masson , Ryan Pauline M. , Zheng Bo , Afif-Rider Shameen , Yu Xiang Qing , Gunsior Michele , Zhong Haihong , Harper Jay , Bezabeh Binyam , Vashisht Kapil , Rebelatto Marlon , Reed Molly , Ryan Patricia C. , Breen Shannon , Patel Neki , Chen Cui , Masterson Luke , Tiberghien Arnaud , Howard Phillip W. , Dimasi Nazzareno , Dixit Rakesh
Published: April 2023

Supplementary Figure 1. (a,b) Structure of the payloads SG3249 and SG3400; Supplementary Figure 2. PK concentration vs. time profile of R347-SG3400 in monkeys after either a single IV injection of 4.5mg/kg or 3 weekly IV injections of 1.5mg/kg; Supplementary Table 1. Ocular findings in rats after single or fractionated dosing with IC1-SG3249*
Supplementary Figure 2: Representative Hematology Data from Non-Human Primates Dosed with TTI-621. from TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding
Authors: Petrova Penka S. , Viller Natasja Nielsen , Wong Mark , Pang Xinli , Lin Gloria H.Y. , Dodge Karen , Chai Vien , Chen Hui , Lee Vivian , House Violetta , Vigo Noel T. , Jin Debbie , Mutukura Tapfuma , Charbonneau Marilyse , Truong Tran , Viau Stephane , Johnson Lisa D. , Linderoth Emma , Sievers Eric L. , Maleki Vareki Saman , Figueredo Rene , Pampillo Macarena , Koropatnick James , Trudel Suzanne , Mbong Nathan , Jin Liqing , Wang Jean C.Y. , Uger Robert A.
Published: April 2023

This figure shows representative hematology data from non-human primates (cynomolgus monkeys) dosed with TTI-621.
Supplementary Figure 1: Gating strategy and representative dot plots for flow cytometry-based phagocytosis assay. from TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding
Authors: Petrova Penka S. , Viller Natasja Nielsen , Wong Mark , Pang Xinli , Lin Gloria H.Y. , Dodge Karen , Chai Vien , Chen Hui , Lee Vivian , House Violetta , Vigo Noel T. , Jin Debbie , Mutukura Tapfuma , Charbonneau Marilyse , Truong Tran , Viau Stephane , Johnson Lisa D. , Linderoth Emma , Sievers Eric L. , Maleki Vareki Saman , Figueredo Rene , Pampillo Macarena , Koropatnick James , Trudel Suzanne , Mbong Nathan , Jin Liqing , Wang Jean C.Y. , Uger Robert A.
Published: April 2023

This figure shows our gating strategy and representative dot plots for our flow cytometry-based phagocytosis assay.
Figure S4 from Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma
Authors: Depreeuw Jeroen , Stelloo Ellen , Osse Elisabeth M. , Creutzberg Carien L. , Nout Remi A. , Moisse Matthieu , Garcia-Dios Diego A. , Dewaele Michael , Willekens Karen , Marine Jean-Christophe , Matias-Guiu Xavier , Amant Frédéric , Lambrechts Diether , Bosse Tjalling
Published: April 2023

MDM4 protein expression in the validation cohort (n=48).